Medications employed in managing the movement disorder known as Parkinson’s disease. The two main dopa-decarboxylase inhibitors, co-beneldopa and co-careldopa, are combinations of levodopa with benserazide and levodopa with carbidopa, respectively. These drugs prevent the activation of levodopa except within the brain, thereby reducing the occurrence of common side effects like nausea and vomiting.